Christophe Beauduin

Christophe is a partner in Cooley’s New York office, where he focuses on advising a wide variety of life sciences companies researching, discovering, developing and marketing products in various therapeutic areas and across all stages of development. Christophe works closely with his clients in connection with their overall licensing and partnering strategy and assists them in the structuring, drafting and negotiating of complex strategic business development transactions – including research and discovery relationships, clinical product collaborations and commercial stage agreements.

Christophe’s recent transactions include representing:

• Flare Therapeutics in its 2024 strategic discovery collaboration with Roche to leverage Flare Therapeutics’ proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology – including $70 million in upfront cash and up to $1.8 billion in discovery, development and commercialization milestone payments potentially exceeding $1.8 billion and royalties
• Scorpion Therapeutics in its:
  • 2023 exclusive license agreement with Pierre Fabre to co-develop and commercialize STX-721 and STX-241, two next-generation mutant epidermal growth factor receptor (EGFR) inhibitors for patients with EGFR-mutant non-small cell lung cancer – including a combined $65 million in upfront payment and achievement of near-term milestones and up to a total of $553 million in potential milestone payments, plus royalties
  • 2022 collaboration agreement with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment – including an upfront cash payment of $75 million and additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low double digits and a potential co-development and co-promotion option
• Beam Therapeutics on its agreement with Eli Lilly and Company for Lilly to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics – including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base-editing programs for cardiovascular disease, together with $200 million in combined upfront payment and $50 million in equity investment, as well as up to $350 million in potential future development-stage payments upon completion of certain clinical, regulatory and alliance events – for a total of up to $600 million in potential total deal consideration
  • $70+ million multiyear discovery collaboration and option agreement*
  • $50+ million target discovery collaboration agreement*
  • $100 million in-license of formulation technology*
  • $1.5+ billion oncology development and commercialization collaboration agreement*
  • $170 million out-license of development program*

* Transaction handled prior to joining Cooley 

Before joining Cooley, Christophe served as assistant general counsel for business development at Bristol Myers Squibb, where he led and coordinated legal support for business development transactions, with a focus on the fields of cell therapy, hematology, and research-enabling technologies and platforms.